This case marks another development in the years-long efforts to make psilocybin legally accessible for patients for therapeutic purposes.
On Friday, October 20th, the Ninth Circuit Court of Appeals heard Aggarwal v. United States Drug Enforcement Administration, which centered around the efforts of Sunil Aggarwal, MD to be able to provide psilocybin for terminally ill patients and patients with anxiety and depression (1,2). Dr. Aggarwal, a palliative care physician, is a co-founder of the Advanced Integrative Medical Science Institute (AIMS), which is “an outpatient clinic and research institute dedicated to advancing integrative medical care, research, and education within oncology, psychiatry, neurology, rehabilitation, pain, and palliative care,” (2). For the past few years, he and his team have been taking legal actions to make psilocybin widely and legally accessible, including filing a petition to reschedule psilocybin, which was denied by the Drug Enforcement Administration (DEA) in September 2022 (1,2).
“The [current] case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin (commonly called magic mushrooms) from a highly restricted Schedule I drug to a less restricted Schedule II so that it can be accessed by physicians and other providers to help those with terminal and other life-threatening conditions,” stated a press release on the AIMS website (2). “This case focuses on DEA’s long history of applying an inaccurate test to rescheduling petitions. The outcome of this case could have implications for other emerging and promising therapies.”
Other statements presented by the lawyers representing Dr. Aggarwal included arguments that the DEA did not fully consider the evidence that they had presented in their petition supporting psilocybin as having current accepted medical use, and the argument that the petition should be referred to the Department of Health and Human Services (HHS) (1).
Watch the full case here (starting at 1 hour and 36 minutes into the clip).
For in-depth insight into Dr. Aggarwal’s accomplishments and goals, read The Path to Legalized, Accessible Psilocybin Therapy from our psychedelics issue,Psychedelics: New Frontiers in Alternative Medicine.
References
House Budget Bill Amendment Could End Veterans Affairs Medical Cannabis Ban
July 14th 2025The “Big, Beautiful Bill” signed recently into law by President Donald Trump, includes an amendment that may end the medical cannabis ban in the VA which has prevented doctors from recommending the plant to their patients.
Ep 27: Tracking Strains in Diverse Landscapes
July 2nd 2025In this latest installment of Noid Knowledge, we are joined by Daniela Vergara, PhD, Hemp Specialist at the Cornell Cooperative Extension, and Anna Schwabe, PhD, Associate Lecture Professor at the University of Colorado, discussing the evolution of cannabis cultivation and the need for regional climate data. Their recent project, funded by the Agricultural Genomics Foundation, studies 10 cannabis varieties grown by farmers in different regions, specifically plant characteristics, soil type, and harvest metrics. They aim to understand how environmental factors affect cannabis yield and quality, providing actionable insights for farmers and breeders.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.